Tanox, Sunol tissue factor deal

TNOX agreed to acquire for stock and cash Sunol Molecular's tissue factor antagonist program to treat inflammatory diseases and cancer. TNOX will issue 800,000 shares and pay $6 million to Sunol Molecular (Miramar, Fla.). Based on TNOX's Thursday close of $10.33, the deal is valued at $14.3 million. ...